Skip to main content

Rhythm Pharmaceuticals Inc(RYTM-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Latest News

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
GlobeNewswire - Wed Nov 6, 7:00AM CST
GlobeNewswire
Wed Nov 6, 7:00AM CST
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
GlobeNewswire - Tue Nov 5, 3:01PM CST
GlobeNewswire
Tue Nov 5, 3:01PM CST
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeekยฎ 2024
GlobeNewswire - Mon Nov 4, 3:01PM CST
GlobeNewswire
Mon Nov 4, 3:01PM CST
Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
GlobeNewswire - Thu Oct 24, 5:00AM CDT
GlobeNewswire
Thu Oct 24, 5:00AM CDT
Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024
GlobeNewswire - Wed Oct 23, 7:00AM CDT
GlobeNewswire
Wed Oct 23, 7:00AM CDT
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GlobeNewswire - Tue Oct 8, 3:01PM CDT
GlobeNewswire
Tue Oct 8, 3:01PM CDT
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
PR Newswire - Thu Oct 19, 2023
PR Newswire
Thu Oct 19, 2023
/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...
What Will Amgen Buy Next?
Motley Fool - Thu Jun 29, 2023
Motley Fool
Thu Jun 29, 2023
The biotech could pursue these two budget-friendly targets.
3 Breakout Growth Stocks to Buy for the Long Haul
Motley Fool - Mon Jan 9, 2023
Motley Fool
Mon Jan 9, 2023
These three have had big-time share gains backed up by breakthrough science.
Wall Street - Wall Street Sign NYSE
Stocks Mixed As Fed Rate Hike Looms
Barchart - Thu Sep 15, 2022
Barchart
Thu Sep 15, 2022
September S&P 500 futures (ESU22) are moderately up +0.03% this morning after three major US benchmark indices bounced back during the regular session as an on-target inflation report mainly stopped the flow of Tuesday's sell-off
3 Healthcare Stocks That Are Beating the Market
Motley Fool - Sun Aug 28, 2022
Motley Fool
Sun Aug 28, 2022
Here's why our roundtable is bullish on Shockwave Medical, Axsome Therapeutics, and Rhythm Pharmaceuticals.
What Bear Market? These 3 Stocks Have Been Rocketing Higher in 2022
Motley Fool - Thu Aug 25, 2022
Motley Fool
Thu Aug 25, 2022
These three healthcare stocks have defied the 2022 bear market.
Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference
Globe Newswire - Wed Aug 3, 2022
Globe Newswire
Wed Aug 3, 2022
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on...
Why Rhythm Pharmaceuticals Stock Is Rocketing Higher Today
Motley Fool - Tue Aug 2, 2022
Motley Fool
Tue Aug 2, 2022
The biotech's second-quarter earnings report is a big hit with shareholders.
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update
Globe Newswire - Tue Aug 2, 2022
Globe Newswire
Tue Aug 2, 2022
-- Received FDA approval for IMCIVREEยฎ (setmelanotide) as the first-ever therapy for patients with Bardet-Biedl syndrome -- -- U.S. launch off to a...
Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France
Globe Newswire - Wed Jul 20, 2022
Globe Newswire
Wed Jul 20, 2022
-- Reimbursed early access program allows for patients in France to receive setmelanotide for treatment of obesity and control of hunger associated with...
NICE Recommends Rhythmโ€™s โ–ผIMCIVREEยฎ (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency
Globe Newswire - Mon Jul 18, 2022
Globe Newswire
Mon Jul 18, 2022
- IMCIVREE will be funded and available for use within 90 days in the National Health Service - BOSTON, July 18, 2022 (GLOBE NEWSWIRE) -- Rhythm...
Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity
Globe Newswire - Tue Jul 12, 2022
Globe Newswire
Tue Jul 12, 2022
--All evaluable patients (N=11) achieved BMI decrease of more than 5 percent at 16 weeks on setmelanotide therapy-- --17.2 percent mean reduction in BMI...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Globe Newswire - Fri Jul 8, 2022
Globe Newswire
Fri Jul 8, 2022
BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on...
Rhythm Pharmaceuticals Launches IMCIVREEยฎ (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency
Globe Newswire - Wed Jun 22, 2022
Globe Newswire
Wed Jun 22, 2022
BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to...
Rhythm Pharmaceuticals Announces that European Commission Authorized Variation for IMCIVREEยฎ (setmelanotide) to Allow for Dosing in Patients with POMC or LEPR deficiency with Renal Impairment
Globe Newswire - Wed Jun 22, 2022
Globe Newswire
Wed Jun 22, 2022
BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to...
Stocks-Money-Rates - Tall Buildings in New York City -J4M9FKPEaUA-unsplash
Stocks Bounce Back Ahead of Todayโ€™s Triple-Witching Expiry
Barchart - Fri Jun 17, 2022
Barchart
Fri Jun 17, 2022
Morning Markets September S&P 500 futures (ESU22 ) this morning are up by +1.00%. Stock indexes futures are recovering from Thursdayโ€™s rout that took the S&P 500 down to a 1-1/2 year low. Today brings the quarterly expiration of stock futures and options known as triple witching. The market is...
Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million
Globe Newswire - Thu Jun 16, 2022
Globe Newswire
Thu Jun 16, 2022
Extends Cash Runway into 2H 2024...
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREEยฎ (setmelanotide) for Use in Patients with Bardet-Biedl Syndrome
Globe Newswire - Thu Jun 16, 2022
Globe Newswire
Thu Jun 16, 2022
-- IMCIVREE now available for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Globe Newswire - Thu Jun 2, 2022
Globe Newswire
Thu Jun 2, 2022
BOSTON, June 02, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to...